ENTERA BIO
Jerusalem
About ENTERA BIO
Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience and networks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $30.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: nasdaq:ENTX
- Website: enterabio.com
- Phone: 972-2-532-7151
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/entera-bio-39954 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.